The Future of Peptide Regulation in the United States

Peptide regulation in the United States is in transition. Many peptides popular in wellness circles were restricted from compounding in 2023, but in 2026 the FDA sent several back for advisory review, and in July 2026 an FDA advisory committee narrowly recommended allowing six of them to be compounded. Those votes are not approvals: FDA rulemaking is still pending, and as of this writing none of those peptides may be legally compounded yet.

How Peptide Regulation Works Today

To understand where things are heading, it helps to know the three main routes a peptide can reach a patient:

1. FDA-approved drugs. These went through clinical trials and FDA review for a specific indication. Examples include semaglutide and tirzepatide, tesamorelin (for HIV-associated abdominal fat), bremelanotide (for a form of low sexual desire in premenopausal women), and, as of September 2025, elamipretide for Barth syndrome.
2. Compounded medications. Under section 503A, a licensed pharmacy can prepare a medication for an individual patient's prescription, but only from bulk substances that meet certain criteria, such as being part of an approved drug, having a USP monograph, or appearing on FDA's 503A bulks list. Outsourcing facilities under 503B follow a separate framework. For more, see The FDA 503A vs. 503B Pharmacy Distinction.
3. "Research use only" products. These are sold online, labeled not for human use, and fall outside any patient-care pathway.

While FDA evaluates nominated substances, it uses interim categories. "Category 1" substances may generally be compounded during review; "Category 2" substances raise significant safety concerns and should not be.

The Timeline So Far

• 2023: FDA placed many popular peptides in Category 2, including BPC-157, TB-500, KPV, Semax, MOTS-c, Epitalon, DSIP, ipamorelin, CJC-1295 and others, citing concerns about immune reactions, impurities and limited human safety data.
• 2024: The Pharmacy Compounding Advisory Committee (PCAC) voted against adding ipamorelin, CJC-1295, AOD-9604, MK-677 and kisspeptin-10 to the bulks list.
• April 15, 2026: FDA removed 12 peptides from Category 2 so the PCAC could review them. Removal from Category 2 is not permission to compound.
• July 2026: The PCAC voted to recommend BPC-157, TB-500 and KPV (8 to 6 each), Semax, MOTS-c and Epitalon by similarly narrow margins. It narrowly declined to recommend DSIP. FDA staff had recommended against all of them.
• Still pending: FDA must decide whether to accept the recommendations, then complete notice-and-comment rulemaking. LL-37, Dihexa, Melanotan II and injectable GHK-Cu are slated for committee review before February 2027.

What the Future of Peptide Regulation Could Look Like

No one can predict the final outcome, but several realistic scenarios are worth understanding.

Some peptides added, with conditions

FDA could add certain peptides to the bulks list, possibly limited to particular routes of administration or with quality requirements. This would allow licensed pharmacies to compound them for individual prescriptions.

Some remain restricted

The close votes, and FDA staff's opposing recommendations, suggest FDA may not accept every recommendation. Peptides with weaker data, or with specific safety signals, could remain unavailable.

More pharmaceutical development

The commercial success of GLP-1 medications and the 2025 approval of elamipretide show that peptides can complete the formal drug pathway. Over time, more peptides may arrive as FDA-approved products with defined indications, dosing and safety monitoring, which is the strongest form of evidence for patients.

Continued attention to unregulated sellers

Regardless of compounding decisions, products marketed for "research use only" and sold directly to consumers are likely to remain outside the legal patient-care pathway.

Why the Process Takes So Long

Patients are often frustrated by how slowly this moves. Rulemaking requires FDA to publish a proposed rule, accept public comments, respond to them and then issue a final rule, which can take many months or longer. The evidence behind many of these peptides is also thin in humans, which makes the safety review harder. The committee's split votes reflect genuine scientific disagreement, not just bureaucracy.

What These Changes Mean for Patients

It is easy to read headlines and conclude that a peptide is now "approved" or "proven." Neither is true. Three distinctions matter:

• Allowed to be compounded is not the same as FDA-approved. Compounded drugs are not reviewed by FDA for safety or effectiveness for a specific use.
• A favorable committee vote is not evidence of benefit. For BPC-157, for example, most data still come from animal studies, as I discuss in BPC-157: What the Evidence Does and Does Not Show.
• Quality still varies. Even if compounding becomes permitted, sourcing, sterility and testing standards remain essential.

How I Approach This at Laeeq M.D.

In my practice, I follow FDA status closely and use only medications that are legally available through appropriate pharmacies. Every peptide discussion starts with a full internal medicine evaluation and labs, and dosing is individualized only after that evaluation. When a compound is not legally available, I say so plainly and focus on the evidence-based options that are. Patients in Reston, VA, and across our served states can review compound summaries in the peptide library and read more in Are Peptides FDA-Approved? What Patients Need to Know.

Sources

• US Food and Drug Administration. "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." FDA, updated 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
• "FDA Panel Backs 6 Peptides for Compounding." AJMC, July 31, 2026. https://ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
• US Food and Drug Administration. "FDA Grants Accelerated Approval to First Treatment for Barth Syndrome." FDA, September 19, 2025. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome

Book a Consultation

If you are trying to make sense of peptide news and what is actually available, a physician-led conversation helps. You can book a consultation with Dr. Laeeq for a 60-minute evaluation, virtual or in person in Reston, VA, to review your goals, labs and legal, evidence-based options.

This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.